Lexeo Therapeutics (LXEO) Restructuring Costs (2024 - 2026)

Lexeo Therapeutics has disclosed Restructuring Costs across 3 years of filings, most recently posting $4.7 million for Q1 2026.

• Restructuring Costs for Q1 2026 came in at $4.7 million, down 62.52% year-over-year; the trailing twelve-month figure through Mar 2026 was $29.1 million (down 10.78% YoY), and the FY2025 annual result was $37.0 million, up 48.06% from the prior year.
• Restructuring Costs came in at $4.7 million for Q1 2026 at Lexeo Therapeutics, down from $9.3 million in the prior quarter.
• In the past five years, Restructuring Costs ranged from a high of $12.6 million in Q1 2025 to a low of $2.9 million in Q3 2025.
• The 3-year median for Restructuring Costs is $4.9 million (2024), against an average of $7.4 million.
• Across the five-year window, Restructuring Costs surged 209.04% in 2025 and plunged 62.52% in 2026, its largest moves.
• Lexeo Therapeutics' Restructuring Costs stood at $11.8 million in 2024, then fell by 21.02% to $9.3 million in 2025, then sank by 49.47% to $4.7 million in 2026.
• The last three Restructuring Costs figures came in at $4.7 million (Q1 2026), $9.3 million (Q4 2025), and $2.9 million (Q3 2025), per Business Quant data.